Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

AARP TARGETING PHYSICIANS WITH PRO-GENERIC ADS that describe 10 myths and facts about generic drugs. The American Association of Retired Persons (AARP) ads appeared in three parts in The New England Journal of Medicine Oct. 16, Oct. 23, and Oct. 30 issues. Together, the three ads reprint in entirety an article written by FDA, which was entitled "Myths vs. Facts About Generic Drugs" and was published in the April, 1986 issue of the National Association of Boards of Pharmacy newsletter. Each of the three ads contains a statement by AARP explaining why the association had the article reprinted: "We have become alarmed at the aggressive misinformation campaign being waged by some research-intensive pharmaceutical firms against generic drugs. Our members, and other older Americans, are the ultimate victims of these uncompetitive practices. We are presenting the following Myths vs. Facts . . . in an effort to set the record straight." The ads also contain a coupon for requesting reprints of the Myths vs. Facts article and/or copies of another FDA article, aimed towards patients, entitled "Generic Drugs: Cutting Costs Not Corners." AARP said the association has received "hundreds of requests" from physicians for reprints. FDA notes in the Myths article that "there have been many challenges from a wide variety of sources about the relative merits of generic drugs versus their brandname predecessors and about the FDA's ability to ensure that generic drugs are equivalent to the brandname drugs they are copying." This article, FDA states, "discusses and rebuts from FDA's perspective 10 charges or myths currently being raised by brandname firms, directly or through intervening sources under the guise of independent scientific dialogue, aimed at discouraging health professionals from prescribing or dispensing generic drugs." One "myth," for example, states that "bioequivalence testing is not an indicator of how the drug will perform in patients" since bioequivalence testing is done in healthy, young volunteers instead of the patient population who will be using the drug. The "fact," FDA states, is that "testing in healthy volunteers, which shows an equivalent blood level between the generic and the name brand product, is a strong indicator that the two tested dosage forms will behave the same under the same conditions." AARP said the three journal ads cost the association approximately $10,000. AARP Health Analyst Judi Brown noted that the association is currently attempting to publish the Myths article in Generics magazine (produced by the Generic Pharmaceutical Industry Association).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts